Prevalence and Risk Factors for Adrenal Insufficiency in Patients with Multiple Myeloma Receiving Long-Term Chemotherapy including Corticosteroids: A Retrospective Cohort Study
Table 2
Corticosteroid treatment during chemotherapy in patients with multiple myeloma according to the presence of adrenal insufficiency.
Variables
No-AI ()
AI ()
Duration of follow-up (months)
27.0 (10.0–59.8)
22.0 (7.0–45.0)
0.076
Number of changes in chemotherapy regimen
0.497
Type of corticosteroid
0.367
Prednisolone only
19 (13.6)
27 (19.0)
Dexamethasone only
37 (26.4)
40 (28.2)
Combinationa
84 (60.0)
75 (52.8)
Cumulative dose of corticosteroids (mg)b
28834 (12511–62262)
25632 (11333–50712)
0.013
Cumulative duration of corticosteroid use (days)
58.5 (21.3–136.5)
47.5 (24.0–102.0)
0.135
Cumulative dose/duration of corticosteroid use (mg/day)b
525.9 (326.7–766.5)
456.2 (310.7–763.1)
0.803
Megestrol acetate use in the last chemotherapy regimen
22 (15.7)
47 (33.1)
0.001
Data are presented as or median (interquartile range) or (%). aEleven patients who had a history of methylprednisolone use were included. bCorticosteroid doses were expressed in prednisolone equivalents.
